# DaVita (DVA) Financial Model Free Excel 3-statement financial model and company analysis for DaVita. - Canonical: https://finamodel.com/companies/davita - Industry: Healthcare Services - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/DVA.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for DaVita Inc. (DVA), enabling an analyst to forecast free cash flow generation based on U.S. dialysis treatment volumes, payor mix shifts, and the expansion of value-based integrated kidney care. ## Company Overview DaVita Inc. is a leading provider of kidney care services, primarily operating outpatient dialysis centres for patients with end-stage renal disease (ESRD). The company also manages value-based care arrangements through its Integrated Kidney Care (IKC) division and operates an expanding international dialysis network. - **Business segments:** U.S. Dialysis (approx. 88% of revenue), U.S. Ancillary Services / IKC (approx. 7%), International (approx. 5%). - **Key geographies:** United States (vast majority of revenue), with a growing presence in Latin America (Brazil, Colombia, Chile, Ecuador) and Europe. - **Business model type:** Asset-heavy clinic operator with highly recurring, life-sustaining treatment volumes. - **Competitive position:** Duopoly in the U.S. dialysis market alongside Fresenius Medical Care, holding significant market share and pricing power with commercial payors. - **Recent major events:** The inclusion of oral phosphate binders in the Medicare dialysis bundle in January 2025, a $300 million acquisition of Latin American clinics from Fresenius in 2024, and ongoing aggressive share repurchase programmes reducing share count to approximately 66.8 million by early 2026. ## Revenue Deep Dive ### U.S. Dialysis - **Segment name:** U.S. Dialysis - **Revenue driver formula:** Total U.S. Treatments x Average Revenue Per Treatment (RPT) - **Historical growth rate:** 1-3% CAGR (driven by RPT pricing increases, while volume has been flat to slightly negative post-COVID). - **Key growth levers and headwinds:** Headwinds include elevated patient mortality and missed treatments impacting volume, as well as long-term fears regarding GLP-1 drugs reducing ESRD incidence. Levers include commercial rate negotiations and Medicare base rate updates. - **Pricing dynamics:** Highly dependent on payor mix. Commercial insurance pays significantly more than government programmes (Medicare/Medicaid). A 1% shift from commercial to government payors severely impacts margins. - **Revenue recognition notes:** Recognised over time as treatments are administered, net of estimated contractual adjustments and uncollectible accounts. - **Seasonality:** Q1 is typically the weakest for revenue and margins due to the reset of commercial insurance deductibles and co-insurance. ### U.S. Ancillary Services (Integrated Kidney Care) - **Segment name:** U.S. Ancillary Services - **Revenue driver formula:** Covered Lives in Risk-Based Arrangements x Annualised Medical Spend Managed x Shared Savings Rate - **Historical growth rate:** 10-15% CAGR as the company shifts towards value-based care. - **Key growth levers and headwinds:** Driven by Medicare Advantage penetration and the transition to capitated risk models. - **Pricing dynamics:** Revenue is tied to shared savings and capitation rates rather than fee-for-service. - **Revenue recognition notes:** Includes estimated shared savings which are trued up annually based on actual medical cost performance. - **Seasonality:** Shared savings are often recognised in specific quarters when reconciliation data from CMS becomes available. ### International - **Segment name:** International - **Revenue driver formula:** International Treatments x International RPT - **Historical growth rate:** 8-12% CAGR (heavily driven by acquisitions). - **Key growth levers and headwinds:** Expanding footprint in Latin America and Europe; headwinds include foreign currency translation and sovereign reimbursement risks. - **Pricing dynamics:** Regulated by national health systems in respective countries. - **Revenue recognition notes:** Standard fee-for-service recognition, translated to USD. - **Seasonality:** Minimal underlying seasonality, though currency fluctuations create quarter-to-quarter noise. ## Cost Structure ### Variable Costs / COGS - **Line item:** Patient Care Costs - **Gross margin range:** DaVita does not report traditional gross margin; instead, it reports Patient Care Costs. The implied "clinic margin" (Revenue minus Patient Care Costs) is typically 28-32%. - **Key input costs and commodity exposures:** Clinical labour (nurses, technicians), pharmaceuticals (EPO, oral phosphate binders), medical supplies, and clinic lease expenses. - **How COGS scales with revenue:** Step-function. A clinic requires a baseline staffing level regardless of whether it operates at 70% or 90% capacity. High operating leverage on incremental treatments. ### Operating Expenses - **R&D:** Not material for this healthcare services provider. - **SG&A:** Reported as "General and administrative". Typically runs at 9-11% of consolidated revenue. Highly headcount-driven (corporate staff, IT, billing, and collections). - **Depreciation & Amortisation:** Typically 5-6% of revenue. Heavily weighted towards tangible assets (clinic build-outs, medical equipment) and capitalised software. - **Stock-Based Compensation:** Typically 0.5-1.0% of revenue. - **Restructuring / one-time charges:** Frequent clinic closure costs and capacity rationalisation charges (e.g., $72 million in 2024). ### Margin Profile - **Operating margin:** 14.5% to 16.5% (Consolidated adjusted operating margin was 15.3% in 2025). - **Margin trend:** Stable to slightly expanding, as RPT growth (4-5%) outpaces clinical labour inflation. - **Segment-level margins:** U.S. Dialysis generates the vast majority of operating income. Ancillary services operate at near breakeven or low single-digit margins as the IKC business scales. ## Balance Sheet Structure - **Total assets:** Approximately $16-18 billion. - **Key asset categories:** Operating lease right-of-use assets (clinic leases), Goodwill (historical acquisitions like HealthCare Partners, though later divested, and clinic roll-ups), and Property, Plant & Equipment. - **Goodwill & intangibles as % of total assets:** Approximately 35-40%. - **Working capital profile:** - **Days Sales Outstanding (DSO):** 55-65 days (driven by complex billing with Medicare and commercial payors). - **Days Inventory Outstanding (DIO):** 10-15 days (pharmaceuticals and dialysate supplies). - **Days Payable Outstanding (DPO):** 45-55 days. - **Net working capital as % of revenue:** Slightly positive but relatively lean. - **Is working capital positive or negative?** Modestly positive. The company does not rely on negative working capital to fund growth. - **PP&E:** Leasehold improvements for clinics, dialysis machines, and IT infrastructure. Useful life for equipment is typically 5-10 years. - **Right-of-use assets / operating leases:** Highly material. DaVita leases almost all of its 3,100+ clinics. Operating lease liabilities typically exceed $3.5 billion. ## Capital Expenditure & Investment - **Capex as % of revenue:** 4.5% to 6.0%. - **Maintenance capex vs. growth capex:** Approximately 60% maintenance (clinic refurbishments, machine replacements) and 40% growth (new clinic build-outs, IT investments). - **Major capex programmes underway:** Investments in home dialysis infrastructure and IT systems for value-based care tracking. - **Capitalised software / development costs:** Material, related to clinical IT systems (CW1) and billing infrastructure. - **M&A pattern:** Bolt-on acquirer internationally (e.g., Fresenius Latin America assets) and domestic joint ventures with nephrology practices. - **Typical acquisition multiple paid:** 7x to 9x EBITDA for independent clinics. ## Debt & Capital Structure - **Total debt:** Approximately $8.5 to $9.5 billion. - **Debt/EBITDA ratio:** Target leverage is 3.0x to 3.5x. - **Credit rating:** Non-investment grade (typically Ba2/BB). - **Key debt instruments:** Senior secured credit facilities (Term Loan A and B) and unsecured senior notes. - **Maturity profile:** Staggered, with management proactively refinancing 1-2 years ahead of major maturities. - **Interest rate profile:** Mix of fixed and floating. The company uses interest rate swaps to fix a portion of its Term Loan exposure. - **Covenants:** Maximum consolidated leverage ratio and minimum interest coverage ratio under the senior secured credit facility. - **Share repurchase programme:** Highly active. The company repurchased 9.8 million shares in 2024 and continues to aggressively shrink its share base using free cash flow. - **Dividend policy:** No regular dividend. All return of capital is executed via share repurchases. ## Cash Flow Characteristics - **Operating cash flow conversion:** Very strong. OCF is typically 1.5x to 2.0x Net Income due to high depreciation and non-cash charges. OCF was $1.887 billion in 2025. - **Free cash flow margin:** 7.5% to 9.0% ($1.024 billion FCF on $13.643 billion revenue in 2025). - **Major non-cash items:** Depreciation and amortisation, stock-based compensation, and deferred income taxes. - **Working capital cash flow impact:** Generally a minor drag on cash flow as revenue grows, but highly stable. - **Capex intensity:** Moderate (approx. 5% of revenue). - **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are typically lower than the GAAP rate (23-25%) due to accelerated depreciation on medical equipment and clinic build-outs. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for volume growth, RPT, payor mix, cost margins, capex, and debt terms. 2. **U.S. Dialysis Build**: Detailed schedule forecasting Treatments per Day, Operating Days, Total Treatments, RPT, and Patient Care Costs per Treatment. 3. **Ancillary & International Build**: Revenue and margin forecasts for U.S. Ancillary Services (IKC) and International segments. 4. **Income Statement**: Consolidated P&L mirroring the 10-K (Revenues, Patient care costs, General and administrative, Depreciation and amortisation). 5. **Balance Sheet**: Assets, Liabilities, and Equity, explicitly breaking out Operating lease right-of-use assets and liabilities. 6. **Cash Flow Statement**: Operating, Investing, and Financing cash flows, highlighting the massive share repurchase line item. 7. **Debt Schedule**: Tranche-by-tranche debt build, interest expense calculation, and swap impact. 8. **PP&E & Leases**: Capex, depreciation waterfall, and operating lease schedule. 9. **Working Capital**: DSO, DIO, DPO calculations and cash flow bridge. 10. **DCF Valuation**: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price. ## Key Financial Relationships 1. `U.S. Dialysis Revenue = Total U.S. Treatments x U.S. Revenue Per Treatment` 2. `Total U.S. Treatments = Average Treatments Per Day x Operating Days in Period` 3. `U.S. Patient Care Costs = Total U.S. Treatments x Patient Care Cost Per Treatment` 4. `U.S. Dialysis Operating Margin = (U.S. Dialysis Revenue - U.S. Patient Care Costs - Allocated G&A - Allocated D&A) / U.S. Dialysis Revenue` 5. `International Revenue = International Treatments x International RPT` 6. `Consolidated Revenue = U.S. Dialysis Revenue + U.S. Ancillary Revenue + International Revenue` 7. `Consolidated Operating Income = Consolidated Revenue - Patient Care Costs - General and Administrative - Depreciation and Amortisation` 8. `Free Cash Flow = Operating Cash Flow - Distributions to Noncontrolling Interests - Capital Expenditures` 9. `Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchase Spend / Average Share Price)` 10. `Interest Expense = (Average Term Loan Balance x Floating Rate) + (Average Senior Notes Balance x Fixed Rate)` 11. `Leverage Ratio = Total Debt / Adjusted EBITDA` ## Cross-Sheet Dependencies - The **U.S. Dialysis Build** and **Ancillary & International Build** sheets feed directly into the top line of the **Income Statement**. - The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement**. - The **Cash Flow Statement** calculates Free Cash Flow, which determines the cash available for share repurchases on the **Assumptions** and **Debt Schedule** sheets. - The **Debt Schedule** calculates Interest Expense, which feeds back into the **Income Statement** (creating a circular reference that must be managed with a toggle or iterative calculation). - The **PP&E & Leases** sheet calculates Depreciation and Amortisation, feeding both the **Income Statement** and the non-cash add-backs on the **Cash Flow Statement**. ## Sign Convention - Revenues, assets, and equity are positive. - Expenses (Patient care costs, G&A, D&A, Interest) are represented as positive numbers in their specific build schedules but subtracted in the Income Statement totals. - Cash outflows (Capex, share repurchases, debt paydowns) are negative on the Cash Flow Statement. - Contra-assets (Accumulated Depreciation) are negative. ## Things Most Likely to Go Wrong - **Payor Mix Sensitivity:** Failing to model the outsized impact of commercial payors. A 1% shift from commercial to Medicare can wipe out millions in operating income. - **Treatment Day Math:** Dialysis clinics operate 6 days a week. The number of operating days varies by quarter (e.g., 78 vs 79 days), which artificially swings sequential revenue growth. The model must use treatments per day. - **Noncontrolling Interests (NCI):** DaVita operates many clinics as joint ventures with local nephrologists. NCI distributions are a material cash outflow that must be deducted to reach true Free Cash Flow. - **Share Count Reduction:** DaVita buys back stock relentlessly. Holding share count flat will severely understate future Earnings Per Share. - **Lease Accounting:** Operating lease costs sit in Patient Care Costs and G&A, but the balance sheet carries massive ROU assets and liabilities. Ensure the D&A of these leases is handled correctly per ASC 842. - **Oral Phosphate Binders:** The 2025 inclusion of these drugs in the Medicare bundle creates a one-time step-up in RPT and Patient Care Costs. Historical RPT growth rates will not apply to the 2024-2025 bridge. - **Adjusted vs. GAAP Metrics:** The company frequently reports "Adjusted Operating Income" which excludes clinic closure costs. The model must forecast GAAP metrics and bridge to Adjusted. - **Interest Rate Swaps:** DaVita fixes much of its floating debt. Using a pure SOFR curve on the entire Term Loan balance will overstate interest expense volatility. ## Validation Checks - "Consolidated Operating Margin should remain in the 14.5% to 16.5% range; flag if outside this band." - "Free Cash Flow must be between $1.0 billion and $1.25 billion based on management guidance; flag if outside." - "U.S. Revenue Per Treatment should be approximately $409 to $425; flag if growth exceeds 6% annually." - "Debt/Adjusted EBITDA must remain between 3.0x and 3.5x; flag if leverage exceeds 4.0x." - "Capex as a % of revenue should run between 4.5% and 6.0%." - "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." - "Share count must decrease year-over-year if FCF is positive and leverage is below target." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | U.S. Treatments Per Day | 91,600 | Treatments | Based on Q4 2025 actuals. | | U.S. Operating Days per Year | 312 | Days | Standard 6-day operating week for dialysis clinics. | | U.S. Revenue Per Treatment (RPT) | $410.00 | USD | Blended rate based on FY 2025 actuals. | | U.S. RPT Annual Growth | 4.5% | % | Management guidance for 2025 pricing growth. | | Patient Care Costs per Treatment | $285.00 | USD | Implied from historical clinic margins and 2025 actuals. | | Patient Care Cost Inflation | 3.5% | % | Reflects clinical labour and pharmaceutical cost trends. | | G&A as % of Revenue | 10.0% | % | Historical average from recent 10-K filings. | | D&A as % of Revenue | 5.5% | % | Historical average reflecting clinic and IT depreciation. | | Capex as % of Revenue | 5.0% | % | Consistent with historical maintenance and growth spend. | | Effective Tax Rate | 24.0% | % | Standard corporate rate plus state taxes, net of NCI impact. | | Target Leverage Ratio | 3.25x | Multiple | Midpoint of management's stated 3.0x - 3.5x target. | | Annual Share Repurchase Spend | $800 | USD Millions | Assumes majority of FCF is deployed to buybacks. | | Beginning Shares Outstanding | 66.8 | Millions | Actual share count as of February 2026. | | WACC | 8.5% | % | Standard discount rate for healthcare services. | | Terminal Growth Rate | 1.5% | % | Reflects mature, low-volume-growth nature of U.S. ESRD market. | ## Data Sources & Benchmarks - **Filings:** SEC EDGAR (Form 10-K, 10-Q, 8-K) and DaVita Investor Relations website (investors.davita.com). - **Key peers for benchmarking:** Fresenius Medical Care (FMS), US Physical Therapy (USPH), Encompass Health (EHC). - **Industry data sources:** United States Renal Data System (USRDS) for ESRD incidence and prevalence rates; Centers for Medicare & Medicaid Services (CMS) for final rules on the ESRD Prospective Payment System (PPS). - **Consensus estimates source:** FactSet or Bloomberg for forward-looking RPT and volume estimates. ## Sources - DaVita Inc. Q4 2024 Earnings Release and 2025 Guidance - DaVita Inc. Q4 2025 Earnings Release - DaVita Inc. 2024 Form 10-K and 2025 Form 10-K - Industry Analysis on DaVita Growth Strategy and Medicare Bundle Changes --- ## Frequently asked questions ### What services does DaVita Inc. provide? DaVita Inc. is a leading provider of kidney care services, primarily operating outpatient dialysis centers for patients with end-stage renal disease. The company also manages value-based care arrangements through its Integrated Kidney Care division and has an expanding international dialysis network. ### What are the primary revenue drivers for DaVita's business? DaVita's revenue is primarily driven by U.S. dialysis treatment volumes, shifts in payor mix, and the expansion of its value-based integrated kidney care programs. The company's asset-heavy clinic operator model benefits from highly recurring, life-sustaining treatment volumes. ### What is DaVita's typical capital expenditure as a percentage of revenue? DaVita's capital expenditure typically ranges from 4.5% to 6.0% of its revenue, with the financial model assuming 5.59%. Approximately 60% of this capex is for maintenance, covering clinic refurbishments and machine replacements, while 40% is for growth, such as new clinic build-outs and IT investments. ### What is the assumed revenue growth rate in the DaVita financial model? The DaVita financial model assumes a revenue growth rate of approximately 1.61%. This growth is influenced by factors such as U.S. dialysis treatment volumes, payor mix shifts, and the expansion of value-based integrated kidney care. ### What is the purpose of the DaVita financial model for analysts? The DaVita financial model serves as a comprehensive equity valuation and scenario planning tool. It enables analysts to forecast free cash flow generation based on key operational drivers like U.S. dialysis treatment volumes and payor mix shifts. ### Can I download an Excel financial model for DaVita (DVA)? Yes, an Excel financial model for DaVita (DVA) is available for download. This model provides a detailed forecast horizon from FY2026 to FY2030, allowing for in-depth analysis of the company's future financial performance. [Interactive forecast calculator](https://finamodel.com/companies/davita/forecast)